Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-blind, Placebo-controlled Trial to Determine the Capacity of VAK694 to Elicit Long Term Immune Tolerance When Combined With Subcutaneous Allergen Immunotherapy for the Treatment of Seasonal Allergic Rhinitis.

Next Previous
Trial Profile

Randomized, Double-blind, Placebo-controlled Trial to Determine the Capacity of VAK694 to Elicit Long Term Immune Tolerance When Combined With Subcutaneous Allergen Immunotherapy for the Treatment of Seasonal Allergic Rhinitis.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VAK 694 (Primary) ; Grass pollen allergy immunotherapy
  • Indications Grass pollen hypersensitivity; Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors Novartis

Most Recent Events

  • 31 Oct 2015 Primary endpoint (intra-dermal late phase response to allergen measure: wheal diameter) has been met as per the results published in the Journal of Allergy and Clinical Immunology.
  • 31 Oct 2015 Results published in the Journal of Allergy and Clinical Immunology
  • 24 Apr 2012 Actual end date (October 2011) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top